ReviewClinical and experimental medicine2026
Exploring the applicability, combined strategies, and challenges of ablation in hematology based on its characteristics and immunomodulatory mechanisms.
Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Malignant hematological diseases, such as lymphoma, leukemia, and multiple myeloma, are frequently accompanied by clinical challenges including local progressive lesions, relapsed/refractory conditions, and poor tolerance to standard treatments in special populations. Systemic therapies represented by chemotherapy and targeted therapy have inherent limitations in addressing local tumor burden, relieving organ compression, and being suitable for frail patients. As a minimally invasive local treatment technology, ablation has been widely used in solid tumor therapy due to its advantages of precise targeting, controllable tissue damage, and potential immune activation. However, its application in hematological diseases remains scattered and lacks systematic integration. This review focuses on three mainstream ablation technologies—radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation (CA)—systematically elaborating their core mechanisms, technical advancements, and clinical applications in hematological diseases. We analyze the clinical value of ablation in reducing tumor burden, relieving symptoms, adapting to special populations, intervening in myeloma bone disease, and treating aspergilloma. Additionally, we clarify the indications and contraindications of ablation in hematological diseases. We also discuss in depth the current challenges, including insufficient evidence, technical application boundaries, and limited immunomodulatory effects. Finally, we explore the future development directions of ablation technology in this field from the aspects of clinical evidence construction, treatment strategy optimization—such as combinations with immunotherapy and nanomedicine—and technical popularization and standardization. This review aims to provide a comprehensive theoretical basis and practical reference for the clinical application and in-depth research of ablation technology in hematological diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.